Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

Morie Gertz, Athanasios Anagnostopoulos, Kenneth Anderson, Andrew R. Branagan, Morton Coleman, Stanley R. Frankel, Sergio Giralt, Todd Levine, Nikhil Munshi, Alan Pestronk, S Vincent Rajkumar, Steven P. Treon

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

This presentation represents consensus recommendations for the treatment of patients with Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the second International Workshop held in Athens, Greece during September 2002. The faculty adopted the following statements for the management of patients with Waldenstrom's macroglobulinemia: (1) Alkylating agents, nucleoside analogues, and rituximab are reasonable choices for first line therapy of WM. (2) Both cladribine and fludarabine are reasonable choices for the therapy of WM. (3) Combinations of alkylating agents, nucleoside analogues, or rituximab should at this time be encouraged in the context of a clinical trial. (4) In WM, rituximab can cause a sudden rise in serum IgM and viscosity levels in certain patients, which may lead to complications, therefore close monitoring of these parameters and symptoms of hyperviscosity is recommended for WM patients undergoing rituximab therapy. (5) For relapsed disease, it is reasonable to use an alternate first line agent or re-use of the same agent; however, since autologous stem cell transplantation may have a role in treating patients with relapsed disease it is recommended that for patients in whom autologous transplantation is seriously being considered, exposure to alkylator or nucleoside analogue drugs should be limited. (6) Combination chemotherapy for patients who can tolerate myelotoxic therapy, thalidomide alone or with dexamethasone, can reasonably be considered to have relapsed. (7) Autologous stem cell transplantation may be considered for patients with refractory or relapsing disease. (8) Allogeneic transplantation should only be undertaken in the context of a clinical trial. (9) Plasmapheresis should be considered as interim therapy until definitive therapy can be initiated. (10) Rituximab should be considered for patients with IgM-related neuropathies. (II) Corticosteroids may be useful in the treatment of symptomatic mixed cryoglobulinemia. (12) Splenectomy is rarely indicated but has been used to manage painful splenomegaly and hypersplenism.

Original languageEnglish (US)
Pages (from-to)121-126
Number of pages6
JournalSeminars in Oncology
Volume30
Issue number2
DOIs
StatePublished - Apr 2003

Fingerprint

Waldenstrom Macroglobulinemia
Education
Alkylating Agents
Nucleosides
Therapeutics
Stem Cell Transplantation
Immunoglobulin M
Clinical Trials
Cladribine
Hypersplenism
Cryoglobulinemia
Thalidomide
Plasmapheresis
Autologous Transplantation
Greece
Splenomegaly
Homologous Transplantation
Splenectomy
Combination Drug Therapy
Viscosity

ASJC Scopus subject areas

  • Oncology

Cite this

Treatment recommendations in Waldenstrom's macroglobulinemia : Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. / Gertz, Morie; Anagnostopoulos, Athanasios; Anderson, Kenneth; Branagan, Andrew R.; Coleman, Morton; Frankel, Stanley R.; Giralt, Sergio; Levine, Todd; Munshi, Nikhil; Pestronk, Alan; Rajkumar, S Vincent; Treon, Steven P.

In: Seminars in Oncology, Vol. 30, No. 2, 04.2003, p. 121-126.

Research output: Contribution to journalArticle

Gertz, M, Anagnostopoulos, A, Anderson, K, Branagan, AR, Coleman, M, Frankel, SR, Giralt, S, Levine, T, Munshi, N, Pestronk, A, Rajkumar, SV & Treon, SP 2003, 'Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia', Seminars in Oncology, vol. 30, no. 2, pp. 121-126. https://doi.org/10.1053/sonc.2003.50039
Gertz, Morie ; Anagnostopoulos, Athanasios ; Anderson, Kenneth ; Branagan, Andrew R. ; Coleman, Morton ; Frankel, Stanley R. ; Giralt, Sergio ; Levine, Todd ; Munshi, Nikhil ; Pestronk, Alan ; Rajkumar, S Vincent ; Treon, Steven P. / Treatment recommendations in Waldenstrom's macroglobulinemia : Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. In: Seminars in Oncology. 2003 ; Vol. 30, No. 2. pp. 121-126.
@article{1ca1ec1351af47cb874dc67bee245670,
title = "Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia",
abstract = "This presentation represents consensus recommendations for the treatment of patients with Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the second International Workshop held in Athens, Greece during September 2002. The faculty adopted the following statements for the management of patients with Waldenstrom's macroglobulinemia: (1) Alkylating agents, nucleoside analogues, and rituximab are reasonable choices for first line therapy of WM. (2) Both cladribine and fludarabine are reasonable choices for the therapy of WM. (3) Combinations of alkylating agents, nucleoside analogues, or rituximab should at this time be encouraged in the context of a clinical trial. (4) In WM, rituximab can cause a sudden rise in serum IgM and viscosity levels in certain patients, which may lead to complications, therefore close monitoring of these parameters and symptoms of hyperviscosity is recommended for WM patients undergoing rituximab therapy. (5) For relapsed disease, it is reasonable to use an alternate first line agent or re-use of the same agent; however, since autologous stem cell transplantation may have a role in treating patients with relapsed disease it is recommended that for patients in whom autologous transplantation is seriously being considered, exposure to alkylator or nucleoside analogue drugs should be limited. (6) Combination chemotherapy for patients who can tolerate myelotoxic therapy, thalidomide alone or with dexamethasone, can reasonably be considered to have relapsed. (7) Autologous stem cell transplantation may be considered for patients with refractory or relapsing disease. (8) Allogeneic transplantation should only be undertaken in the context of a clinical trial. (9) Plasmapheresis should be considered as interim therapy until definitive therapy can be initiated. (10) Rituximab should be considered for patients with IgM-related neuropathies. (II) Corticosteroids may be useful in the treatment of symptomatic mixed cryoglobulinemia. (12) Splenectomy is rarely indicated but has been used to manage painful splenomegaly and hypersplenism.",
author = "Morie Gertz and Athanasios Anagnostopoulos and Kenneth Anderson and Branagan, {Andrew R.} and Morton Coleman and Frankel, {Stanley R.} and Sergio Giralt and Todd Levine and Nikhil Munshi and Alan Pestronk and Rajkumar, {S Vincent} and Treon, {Steven P.}",
year = "2003",
month = "4",
doi = "10.1053/sonc.2003.50039",
language = "English (US)",
volume = "30",
pages = "121--126",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Treatment recommendations in Waldenstrom's macroglobulinemia

T2 - Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

AU - Gertz, Morie

AU - Anagnostopoulos, Athanasios

AU - Anderson, Kenneth

AU - Branagan, Andrew R.

AU - Coleman, Morton

AU - Frankel, Stanley R.

AU - Giralt, Sergio

AU - Levine, Todd

AU - Munshi, Nikhil

AU - Pestronk, Alan

AU - Rajkumar, S Vincent

AU - Treon, Steven P.

PY - 2003/4

Y1 - 2003/4

N2 - This presentation represents consensus recommendations for the treatment of patients with Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the second International Workshop held in Athens, Greece during September 2002. The faculty adopted the following statements for the management of patients with Waldenstrom's macroglobulinemia: (1) Alkylating agents, nucleoside analogues, and rituximab are reasonable choices for first line therapy of WM. (2) Both cladribine and fludarabine are reasonable choices for the therapy of WM. (3) Combinations of alkylating agents, nucleoside analogues, or rituximab should at this time be encouraged in the context of a clinical trial. (4) In WM, rituximab can cause a sudden rise in serum IgM and viscosity levels in certain patients, which may lead to complications, therefore close monitoring of these parameters and symptoms of hyperviscosity is recommended for WM patients undergoing rituximab therapy. (5) For relapsed disease, it is reasonable to use an alternate first line agent or re-use of the same agent; however, since autologous stem cell transplantation may have a role in treating patients with relapsed disease it is recommended that for patients in whom autologous transplantation is seriously being considered, exposure to alkylator or nucleoside analogue drugs should be limited. (6) Combination chemotherapy for patients who can tolerate myelotoxic therapy, thalidomide alone or with dexamethasone, can reasonably be considered to have relapsed. (7) Autologous stem cell transplantation may be considered for patients with refractory or relapsing disease. (8) Allogeneic transplantation should only be undertaken in the context of a clinical trial. (9) Plasmapheresis should be considered as interim therapy until definitive therapy can be initiated. (10) Rituximab should be considered for patients with IgM-related neuropathies. (II) Corticosteroids may be useful in the treatment of symptomatic mixed cryoglobulinemia. (12) Splenectomy is rarely indicated but has been used to manage painful splenomegaly and hypersplenism.

AB - This presentation represents consensus recommendations for the treatment of patients with Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the second International Workshop held in Athens, Greece during September 2002. The faculty adopted the following statements for the management of patients with Waldenstrom's macroglobulinemia: (1) Alkylating agents, nucleoside analogues, and rituximab are reasonable choices for first line therapy of WM. (2) Both cladribine and fludarabine are reasonable choices for the therapy of WM. (3) Combinations of alkylating agents, nucleoside analogues, or rituximab should at this time be encouraged in the context of a clinical trial. (4) In WM, rituximab can cause a sudden rise in serum IgM and viscosity levels in certain patients, which may lead to complications, therefore close monitoring of these parameters and symptoms of hyperviscosity is recommended for WM patients undergoing rituximab therapy. (5) For relapsed disease, it is reasonable to use an alternate first line agent or re-use of the same agent; however, since autologous stem cell transplantation may have a role in treating patients with relapsed disease it is recommended that for patients in whom autologous transplantation is seriously being considered, exposure to alkylator or nucleoside analogue drugs should be limited. (6) Combination chemotherapy for patients who can tolerate myelotoxic therapy, thalidomide alone or with dexamethasone, can reasonably be considered to have relapsed. (7) Autologous stem cell transplantation may be considered for patients with refractory or relapsing disease. (8) Allogeneic transplantation should only be undertaken in the context of a clinical trial. (9) Plasmapheresis should be considered as interim therapy until definitive therapy can be initiated. (10) Rituximab should be considered for patients with IgM-related neuropathies. (II) Corticosteroids may be useful in the treatment of symptomatic mixed cryoglobulinemia. (12) Splenectomy is rarely indicated but has been used to manage painful splenomegaly and hypersplenism.

UR - http://www.scopus.com/inward/record.url?scp=0037399044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037399044&partnerID=8YFLogxK

U2 - 10.1053/sonc.2003.50039

DO - 10.1053/sonc.2003.50039

M3 - Article

C2 - 12720120

AN - SCOPUS:0037399044

VL - 30

SP - 121

EP - 126

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2

ER -